Causes and predictors of early mortality in patients treated with left ventricular assist device implantation in the European Registry of Mechanical Circulatory Support (EUROMACS)
Authors:
- the EUROMACS investigatorsTIthe EUROMACS investigators
- Kadir CaliskanKCKadir Caliskan
Open Access
- 3 February 2020
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine
- Vol. 46 (7) , 1349-1360
Abstract
Purpose The aim of the study was to analyze early mortality after continuous-flow left ventricular assist device (LVAD) implantation which remains high. Methods We analyzed consecutive (n = 2689) patients from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) undergoing continuous-flow LVAD implantation. The primary outcome was early (< 90 days) mortality. Secondary outcomes were differential causes of early post-operative death following LVAD implantation. Results Univariable and multivariable analysis as well as regression analysis were used to examine determinants and differential causes of early (< 90 days) mortality after LVAD implantation. During the first 90 days, 2160 (80%) patients were alive with ongoing LVAD support, 40(2%) patients underwent heart transplantation, and 487(18%) deceased. The main causes of early death were MOF (36%), sepsis (28%), cardiopulmonary failure (CPF; 10%), CVA (9%), and right-sided heart failure (RHF, 8%). Furthermore, MOF and sepsis are 70% of causes of death in the first week. Independent clinical predictors of early death were age, female sex, INTERMACS profile 1 to 3, and ECMO. Laboratory predictors included elevated serum creatinine, total bilirubin, lactate, and low hemoglobin. Furthermore, hemodynamic predictors included elevated RA-to-PCWP ratio, pulmonary vascular resistance, and low systemic vascular resistance. Longer total implantation time was also independent predictor of early mortality. A simple model of 12 variables predicts early mortality following LVAD implantation with a good discriminative power with area under the curve of 0.75. Conclusions In the EUROMACS registry, approximately one out of five patients die within 90 days after LVAD implantation. Early mortality is primarily dominated by multiorgan failure followed by sepsis. A simple model identifies important parameters which are associated with early mortality following LVAD implantation.Keywords
This publication has 37 references indexed in Scilit:
- Continuous-flow devices and percutaneous site infections: Clinical outcomesThe Journal of Heart and Lung Transplantation, 2012
- Right ventricular failure after LVAD implantation: Prevention and treatmentBest Practice & Research Clinical Anaesthesiology, 2012
- Predictor of Early Mortality for Severe Heart Failure Patients With Left Ventricular Assist Device ImplantationCirculation Journal, 2012
- Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classificationThe Journal of Heart and Lung Transplantation, 2011
- Management of Right Ventricular Failure in the Era of Ventricular Assist Device TherapyCurrent Heart Failure Reports, 2011
- Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist DeviceNew England Journal of Medicine, 2009
- Usefulness of the INTERMACS Scale to Predict Outcomes After Mechanical Assist Device ImplantationThe Journal of Heart and Lung Transplantation, 2009
- Anemia and Chronic Heart FailureJACC, 2008
- Right Heart Failure After Left Ventricular Assist Device Implantation in Patients With Chronic Congestive Heart FailureThe Journal of Heart and Lung Transplantation, 2006
- Anemia and Chronic Heart FailureCirculation, 2005